Therapeutic option for infected urinary tract fistulas in renal transplantation

Transplant Proc. 2010 Mar;42(2):479-82. doi: 10.1016/j.transproceed.2010.01.029.

Abstract

Background: Approximately 20% of urinary tract fistulas after renal allografting are complicated by urinary tract infection, which presents a therapeutic challenge.

Objective: To evaluate an option for treatment of urinary tract fistulas associated with urinary tract infection and unsuitable for minimally invasive or primary surgical urinary tract repair.

Patients and methods: The study included 650 recipients who underwent transplantation over 17 years. Urinary leakage was initially treated with indwelling bladder catheterization. Patients with fistulas refractory to treatment underwent surgical intervention to repair the urinary tract. In patients who were not candidates for primary repair of the urinary tract, temporary urinary diversion was performed, rather than classic percutaneous or open nephrostomy, using a ureteral stent (ie, a 6F or 8F Foley catheter with the balloon placed inside the renal pelvis).

Results: Overall, urinary leakage occurred in 36 patients (5.5%). Conservative management was successful in 14 vesical fistulas (42.4%) and no ureteral fistulas (0%). Three patients died of sepsis during conservative treatment, before the new surgical approach. Five of 36 urinary leaks (13.9%) were managed using ureteral intubation with an 8F Foley catheter, with a success rate of 80%.

Conclusion: Ureteral catheterization with an 8F Foley catheter is a feasible therapeutic option to treat complicated urinary tract fistulas unsuitable for primary surgical repair of the urinary tract.

MeSH terms

  • Cadaver
  • Catheterization
  • Drug Therapy, Combination
  • Fistula / complications
  • Fistula / epidemiology*
  • Fistula / mortality
  • Fistula / therapy
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / adverse effects*
  • Laparoscopy / methods
  • Living Donors
  • Retrospective Studies
  • Survival Rate
  • Tissue Donors
  • Urinary Tract Infections / complications
  • Urinary Tract Infections / epidemiology
  • Urinary Tract Infections / mortality
  • Urologic Diseases / complications
  • Urologic Diseases / epidemiology*
  • Urologic Diseases / mortality
  • Urologic Diseases / therapy

Substances

  • Immunosuppressive Agents